Plain-English translation of NCT07234695 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called levetiracetam can help prevent seizures in adults with Down syndrome who have been diagnosed with Alzheimer's disease. People with Down syndrome have a higher risk of developing both Alzheimer's disease and seizures, and the two conditions together can worsen thinking and memory problems. This study will see whether this medication, which is already safely used for seizure treatment, might also help slow cognitive decline.
Adults with Down syndrome are much more likely to develop Alzheimer's disease, and many also experience seizures—a combination that can speed up memory loss and thinking problems. Researchers believe this medication might help prevent seizures and protect brain function in ways beyond its known seizure-preventing effects.
You likely qualify if…
You likely don't qualify if…
You will take either the study medication or a placebo pill twice daily for 96 weeks (almost 2 years). The medication dose will start low for the first 4 weeks to help your body adjust, stay at the full dose in the middle, and then gradually decrease over the final 4 weeks. You will visit the study clinic every 6 months for check-ups, memory and thinking tests, and possibly brain imaging or blood tests to track how you are doing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Spain